Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
5.30
-0.08 (-1.49%)
Nov 4, 2024, 4:00 PM EST - Market closed
Genenta Science Employees
Genenta Science had 14 employees as of December 31, 2023.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$683,040
Market Cap
96.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EDAP TMS | 307 |
| OptiNose | 132 |
| AlloVir | 112 |
| Assertio Holdings | 53 |
| Werewolf Therapeutics | 47 |
| Milestone Pharmaceuticals | 47 |
| Regulus Therapeutics | 30 |
| Renovaro | 25 |
GNTA News
- 12 days ago - Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” - GlobeNewsWire
- 4 weeks ago - Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer - GlobeNewsWire
- 6 months ago - Genenta Welcomes New Directors John L. Cantello, Lauren H. - GlobeNewsWire
- 9 months ago - Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors - GlobeNewsWire
- 1 year ago - Genenta to Present at Upcoming Scientific and Investor Conferences - GlobeNewsWire
- 1 year ago - Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments - GlobeNewsWire
- 1 year ago - The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma - GlobeNewsWire
- 1 year ago - Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing - GlobeNewsWire